[ASC-media] Media Release: Visiting US Scientist Set to Shake up the Promise of Stem Cell Therapy

Daniella Goldberg (Gene Genie Media) daniella at genegeniemedia.com.au
Thu Nov 21 19:05:40 PST 2013


Visiting US Scientist Set to Shake up the Promise of Stem Cell Therapy in
Australia?
- Cynata Therapeutics new stem cell technology applies to broad range of
diseases- 
 
SYDNEY, AUSTRALIA 22 November 2013 ­ Internationally recognised stem cell
scientist, Professor Igor Slukvin, Wisconsin University is visiting
Australia as the key-note speaker at a Stem Cell Meeting in Sydney next
week.
 
He will be introducing a revolutionary stem cell technology to the
Australian bioindustry and revealing how it is likely to shake up the
potential of stem cells.
 
CymerusTM, as the stem cell platform technology is called, has the potential
to create billions of human stem cells from a single embryonic stem cell and
is extremely important in the therapeutic application of stem cells for
patients.
 
Dr Slukvin came up with the invention in the Wisconsin laboratory which is
well-known for being the home of the world¹s first embryonic stem (ES) cell
line made by Professor James Thomson in 1998.
 
³Stem cell therapy has not taken the path that scientists predicted over ten
years ago,² says Dr Slukvin. Currently, one specific stem cell type called
Mesenchymal stem cell, is showing great promise. Mesenchymal stem cells
works by stimulating the body¹s own healing systems.
 
CymerusTM is able to make masses of Mesenchymal stem cells that have the
potential to remedy a broad range of diseases including cardiovascular
disease, diabetes, diseases of the blood, lung, kidney, eyes teeth and
immune system diseases.

Australian biotechnology company, Cynata Therapeutics (ASX:CYP) this week,
renamed and to focus their attention to CymerusTM technology appreciating
the enormous promise it has for stem cell therapeutics. The US company,
Cynata Inc. founded by Professor Slukvin, has just been acquired by the
Australian company to further develop it¹s therapeutic application.
 
Scott Power, Morgan¹s healthcare analyst said, ³there is a growing number of
biotechnology companies focusing their attention on the development of stem
cell therapeutics.²
 
³At the big end of town is Mesoblast (ASX:MSB) and at the smaller end are
biotechs such as Bionomics, Alchemia (ASX:ACL), Allied Healthcare Group
(ASX:AHZ) and Cynata Therapeutics (ASX:CYP) that are developing stem cells.
Also recently, a new stem cell and regeneration company, Regeneus (ASX: RGS)
did a successful IPO.²
 
³We are entering a renaissance period in the biotech sector with healthy
investments over the past 6 months into IPO¹s and capital raisings and stem
cell is one of the emerging areas,² he said.
 
The Workshop - Innovating the Marketplace with Stem Cells ­ on Friday 29
November will take an in depth look what it will take to push the Australian
stem cell industry forward.It is being hosted by the Stem Cell Network for
biotech investors, analysts, clinicians, scientists, policy makers, IP
lawyers, patient advocates, pharma and biotech executives.

Professor Slukvin will be in Melbourne and Sydney prior to the Stem Cell
Workshop.
 
MEDIA INVITE: 
19th Stem Cell Workshop ­ Innovating the Marketplace with Stem Cells ­
8:30am-7pm Friday 29 November at Convention Centre, Darling Harbour, Sydney
Details: http://www.stemcellnetwork.org.au/Workshop/MainFrameSet.html
<http://www.stemcellnetwork.org.au/Workshop/MainFrameSet.html>
 
Speakers Include:
* Prof Igor Slukvin ­ University of Wisconsin
* Scott Power ­ Morgans Ltd.
* Dr Uli Schmidt ­ Genea Biocells
* Professor Geoff Symonds - Calimmune
* Dr Peter Mountford ­ Public Systems Innovation
 
Media Contact
 
For media registration or to arrange interviews:
Daniella Goldberg PhD, Gene Genie Media: Tel: 0416 211 067 eml:
Daniella at genegeniemedia.com.au <mailto:Daniella at genegeniemedia.com.au>
Associate Professor Igor Slukvin - University of Wisconsin,  Cynata
Therapeutics
Igor Slukvin is Associate Professor of Pathology and Cell and Regenerative
Biology at the University of Wisconsin-Madison, USA. His research interests
focus on development of hematopoietic, vascular and mesenchymal lineages
from human pluripotent stem cells. He has published more than 70 papers and
holds key patents in the area of hematovascular cell production from human
pluripotent stem cells. Dr. Slukvin is a scientific founder of CDI in the
United States and Cynata in Australia.
 
About Cynata Therapeutics


Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and
regenerative medicine company that is developing a therapeutic stem cell
platform technology, Cymerus, originating from the University of
Wisconsin-Madison, a world leader in stem cell research.  The proprietary
Cymerus technology seeks to address a critical shortcoming in existing
methods of production of mesenchymal stem cells (MSCs) for therapeutic use,
which is the ability to achieve economic manufacture at commercial scale.
Cymerus does so through the production of a particular type of MSC
precursor, called a mesenchymoangioblast (MCA).   The Cymerus MCA platform
provides a source of MSCs that is independent of donor limitations and
provides a potential ³off-the-shelf² stem cell platform for therapeutic
product use, with a pharmaceutical business model and economies of scale.
This has the potential to create a new standard in the emergent arena of
stem cell therapeutics and provides both a unique differentiator and an
important competitive position.


 

 

Stem Cell Fact Sheet:
Stem Cell Therapies and the Cynata Inc Technology (attached)

 
 
 


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131122/437a64f1/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Stem Cells briefing note November 2013.pdf
Type: application/pdf
Size: 178873 bytes
Desc: not available
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131122/437a64f1/attachment-0001.pdf>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Screen Shot 2013-11-19 at 9.37.49 AM.png
Type: image/png
Size: 108890 bytes
Desc: not available
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131122/437a64f1/attachment-0002.png>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: B5F4D484-D481-4A81-A3EF-FD5A8A9D7C4B.png
Type: image/png
Size: 9062 bytes
Desc: not available
URL: <http://lists.asc.asn.au/pipermail/asc-media/attachments/20131122/437a64f1/attachment-0003.png>


More information about the ASC-media mailing list